Clinical Trial Update: A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

Phase III study evaluating the Port Delivery System with ranibizumab versus monthly injections for wet age-related macular degeneration has completed and result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Port Delivery System with ranibizumab (ranibizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2022-03-25